<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(11)</volume><submitter>Le Rhun E</submitter><pubmed_abstract>&lt;h4>Importance&lt;/h4>Proton pump inhibitors (PPI) are often prescribed to prevent steroid-induced gastritis and peptic ulcer disease in patients with glioblastoma. Yet, these drugs may enhance the activity of aldehyde dehydrogenase 1 A1 (ALDH1A1), which has been linked to protection from oxidative stress, radiotherapy, and chemotherapy.&lt;h4>Objective&lt;/h4>To explore the associations of the use of potent ALDH1A1-activating PPIs (PA-PPIs) and other antacid drugs with outcomes in patients with newly diagnosed glioblastoma.&lt;h4>Design, setting, and participants&lt;/h4>This meta-analysis was a secondary analysis of individual prospectively captured patient data using a dataset of 5 randomized clinical trials conducted between 2008 and 2020. Participants included patients with a new diagnosis of gliobla</pubmed_abstract><journal>JAMA network open</journal><pagination>e2545578</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12648345</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma.</pubmed_title><pmcid>PMC12648345</pmcid><pubmed_authors>Weller M</pubmed_authors><pubmed_authors>Cloughesy T</pubmed_authors><pubmed_authors>Erridge SC</pubmed_authors><pubmed_authors>Nabors B</pubmed_authors><pubmed_authors>Reardon DA</pubmed_authors><pubmed_authors>Preusser M</pubmed_authors><pubmed_authors>Le Rhun E</pubmed_authors><pubmed_authors>Minniti G</pubmed_authors><pubmed_authors>Wick W</pubmed_authors><pubmed_authors>Stupp R</pubmed_authors><pubmed_authors>Sampson J</pubmed_authors><pubmed_authors>Mason W</pubmed_authors><pubmed_authors>Reijneveld JC</pubmed_authors><pubmed_authors>Gorlia T</pubmed_authors><pubmed_authors>Sain D</pubmed_authors><pubmed_authors>Roth P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma.</name><description>&lt;h4>Importance&lt;/h4>Proton pump inhibitors (PPI) are often prescribed to prevent steroid-induced gastritis and peptic ulcer disease in patients with glioblastoma. Yet, these drugs may enhance the activity of aldehyde dehydrogenase 1 A1 (ALDH1A1), which has been linked to protection from oxidative stress, radiotherapy, and chemotherapy.&lt;h4>Objective&lt;/h4>To explore the associations of the use of potent ALDH1A1-activating PPIs (PA-PPIs) and other antacid drugs with outcomes in patients with newly diagnosed glioblastoma.&lt;h4>Design, setting, and participants&lt;/h4>This meta-analysis was a secondary analysis of individual prospectively captured patient data using a dataset of 5 randomized clinical trials conducted between 2008 and 2020. Participants included patients with a new diagnosis of gliobla</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-05T19:55:47.653Z</modification><creation>2026-05-21T03:09:22.198Z</creation></dates><accession>S-EPMC12648345</accession><cross_references><pubmed>41288972</pubmed><doi>10.1001/jamanetworkopen.2025.45578</doi></cross_references></HashMap>